NCT04483687View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

September 30, 2024

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Filgotinib

Tablets administered orally once daily

DRUG

Placebo to Match Filgotinib

Tablets administered orally once daily

Sponsors

Lead Sponsor

Gilead Sciences

Collaborators (1)

Galapagos NV
All Listed Sponsors
collaborator

Galapagos NV

INDUSTRY

lead

Gilead Sciences

INDUSTRY